

14. (Amended) The method of claim 12, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered concurrently with the substance.

15. (Amended) The method of claim 12, wherein the active lipid comprises fully hydrolyzed fats.

16. (Amended) The method of claim 12, wherein the active lipid comprises a fatty acid or a pharmaceutically acceptable salt thereof.

---

19. (Amended) The method of claim 12, wherein the fatty acid comprises oleic acid, a pharmaceutically acceptable oleate salt, or a mixture of either of these with other fatty acids or salts thereof.

20. (Amended) The method of claim 12, wherein oral administration is by ingestion of coated or uncoated microspheres or particles, of a dispersible powder or granule formulation, of a suspension, emulsion, solution, syrup, or elixir, or of a coated or uncoated tablet, troche, capsule, caplet, or lozenge.

21. (Amended) A method of treating a gastrointestinal disorder by slowing the gastrointestinal transit of an orally or enterally administered substance in a subject, comprising administering to a subject in need of the treatment at least one dose of a composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective to promote contact of the lipid with the subject's small intestine and, thereby, slow the gastrointestinal transit of an orally or enterally administered substance through the small intestine.

---